HHS has canceled Moderna’s flu vaccine contract, a move impacting the nation’s pandemic preparedness and the future of mRNA technology. With a $600 million deal scrapped, concerns now mount regarding the United States’ readiness for potential influenza outbreaks, specifically the H5N1 bird flu virus. The decision, impacting vaccine progress for influenza strains, signals a shift in strategy. This cancellation, initiated by the Department of Health and Human Services, comes after an initial review. It raises crucial questions about the role of mRNA vaccines and the future of pandemic responses, especially considering the rapid capabilities of mRNA platforms. news Directory 3 brings you the latest developments as this story unfolds. discover what’s next in the evolving landscape of vaccine development and pandemic preparedness.
HHS Cancels moderna Flu Vaccine Contract, Raising Pandemic concerns
Updated May 29, 2025
The Department of Health and Human Services (HHS) has informed Moderna of its decision to cancel a nearly $600 million contract. The agreement aimed to develop, test, and license vaccines targeting influenza strains, including the H5N1 bird flu virus, that pose a pandemic threat.
While HHS signaled a possible review of the contract, initially signed under the Biden administration, back in February, the cancellation is viewed as a setback for U.S. pandemic preparedness. The contract focused on developing a novel flu vaccine.
The speed at which messenger RNA (mRNA) platforms, like Moderna’s, can produce vaccine doses is unmatched by other methods. However, Health Secretary Robert F. Kennedy Jr. and his supporters reportedly harbor reservations about mRNA vaccine technology and its role in future pandemic responses. The cancellation raises questions about the future role of mRNA vaccines.
